ResMed Inc. (RMD)
223.15 USD -8.15 (-3.52%) Volume: 0.91M
ResMed Inc.’s stock price stands at 223.15 USD, experiencing a dip of -3.52% this trading session with a trading volume of 0.91M, despite an impressive YTD performance gaining +29.72%, showcasing its potential as a strong player in the stock market.
Latest developments on ResMed Inc.
ResMed Inc. (NYSE:RMD) has seen a rise in stock prices today, outperforming the market, following the announcement of a new board member and updates on dividend exchange rates. Despite five-year earnings growth trailing behind favorable shareholder returns, Assenagon Asset Management S.A. continues to hold $6.41 million in stock holdings for ResMed Inc. Investors are keeping a close eye on these developments as they anticipate the impact on the company’s future performance.
ResMed Inc. on Smartkarma
Analysts at Baptista Research have been closely covering Resmed Inc on Smartkarma, providing insights into the company’s performance and growth drivers. In their report titled “ResMed Inc.: A Story Of Increased Market Penetration and New Patient Acquisition! – Major Drivers,” they highlighted ResMed’s robust growth in revenue, amounting to $1.22 billion for the quarter. The company’s focus on innovations in sleep apnea, digital health solutions, and home medical equipment software has been key to their success. The analysts lean bullish on Resmed Inc, citing increased demand and operational excellence as major factors driving the company’s growth.
In another report by Baptista Research titled “ResMed Inc.: What Are Their Latest Products & Their Expected Revenue Impact? – Major Drivers,” analysts discussed ResMed’s strong performance in the third financial quarter of 2024. The company demonstrated strong top-line growth and double-digit bottom-line growth, driven by demand for their devices across global markets. The analysts highlighted high single-digit growth in their Software as a Service business and double-digit global growth in masks and accessories. Despite annualizing a robust quarter of growth from the previous year, Resmed Inc continues to impress analysts with its performance and growth prospects.
A look at ResMed Inc. Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 3 | |
Growth | 4 | |
Resilience | 2 | |
Momentum | 5 | |
OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Resmed Inc has received a mixed outlook based on the Smartkarma Smart Scores. While the company scores high on factors like Growth and Momentum, indicating a positive long-term trajectory, it falls short in areas like Value and Resilience. This suggests that while Resmed Inc shows promise in terms of expansion and market performance, investors may want to consider the company’s overall stability and potential for returns.
Overall, Resmed Inc is a company that focuses on developing and selling medical equipment for sleep disordered breathing. With a strong emphasis on innovation and market presence, the company’s high scores in Growth and Momentum reflect its potential for future success. However, investors should also take into account the lower scores in Value and Resilience, which may indicate some risks and challenges that Resmed Inc could face in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars